Find Reports

Select Report Type

Reimbursement Review

Displaying 576 - 600 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
travoprost ophthalmic solution	Izba	travoprost ophthalmic solution	cdr_SR0516_Izba.pdf SR0516_Izba_complete_Oct-30-17.pdf SR0516_Izba_CL_Report.pdf SR0516_Izba_PE_Report.pdf	Glaucoma and ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2017	Oct 25, 2017	SR0516-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	dysport-therapeutic-product-monograph.pdf SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf SR0517_Dysport_Therapeutic_CL_Report.pdf SR0517_Dysport_Therapeutic_PE_Report.pdf SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf	Upper limb spasticity	Reimburse with clinical criteria and/or conditions	Complete	Apr 24, 2017	Oct 24, 2017	SR0517-000
Darzalex for Multiple Myeloma ...	Darzalex	Daratumumab	pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf	Multiple Myeloma (second-line)	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2017	Oct 5, 2017	PC0104-000
Lynparza for Ovarian Cancer (R...	Lynparza (Resubmission)	Olaparib	pcodr_profund_olaparib_lynparza_resub.pdf pcodr_olaparib_lynparza_resub_fn_rec.pdf pcodr_olaparib_lynparza_resub_fn_cgr.pdf pcodr_olaparib_lynparza_resub_fn_egr.pdf pcodr_olaparib_lynparza_resub_in_rec.pdf pcodr_olaparib_lynparza_resub_pagfdk.pdf pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf pcodr_olaparib_lynparza_resub_ptfdk.pdf pcodr_olaparib_lynparza_resub_clinfdk.pdf pcodr_olaparib_lynparza_resub_coi_pt.pdf pcodr_olaparib_lynparza_resub_coi_clin.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 17, 2017	Sep 20, 2017	PC0103-000
Blincyto for Acute Lymphoblast...	Blincyto (Resubmission)	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_resub.pdf pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf	Acute Lymphoblastic Leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 31, 2017	PC0097-000
Rituxan for Acute Lymphoblasti...	Rituxan	Rituximab	pcodr_profund_rituximab_rituxan_all.pdf pcodr_rituximab_rituxan_all_fn_rec.pdf pcodr_rituximab_rituxan_all_fn_cgr.pdf pcodr_rituximab_rituxan_all_fn_egr.pdf pcodr_rituximab_rituxan_all_in_rec.pdf pcodr_rituximab_rituxan_all_pagfdk.pdf pcodr_rituximab_rituxan_all_fdk_hlroche.pdf pcodr_rituximab_rituxan_all_coi_clinician.pdf	Acute Lymphoblastic Leukemia	Do not reimburse	Complete	Feb 13, 2017	Aug 31, 2017	PC0102-000
Opdivo for Squamous Cell Carci...	Opdivo	Nivolumab	pcodr_profund_nivolumab_opdivo_scchn.pdf pcodr_nivolumab_opdivo_scchn_fn_rec.pdf pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf pcodr_nivolumab_opdivo_scchn_fn_egr.pdf pcodr_nivolumab_opdivo_scchn_in_rec.pdf pcodr_nivolumab_opdivo_scchn_pagfdk.pdf pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf	Squamous Cell Carcinoma of Head and Neck (SCCHN)	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Aug 31, 2017	PC0095-000
Keytruda for Advanced Non-Smal...	Keytruda	Pembrolizumab	PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf	Advanced non-small cell lung carcinoma (first line)	Reimburse with clinical criteria and/or conditions	Complete	Dec 12, 2016	Aug 23, 2017	PC0101-000
Blinatumomab (Blincyto) for Ac...	Blincyto	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf	Acute Lymphoblastic Leukemia (pediatric)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 23, 2017	PC0099 -000
Eliglustat	Cerdelga	Eliglustat	cdr_SR0511_Cerdelga.pdf SR0511_complete_Cerdelga_Jul_28_17_e.pdf SR0511_Cerdelga_CL_Report_e.pdf SR0511_Cerdelga_PE_Report_e.pdf SR0511_Cerdelga_PI_Submissions.pdf	Gaucher disease	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 26, 2017	SR0511-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	cdr_SR0512_Dysport_Therapeutic.pdf SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf SR0512_Dysport_Therapeutic_CL_Report_e.pdf SR0512_Dysport_Therapeutic_PE_Report_e.pdf SR0512_Dysport_Therapeutic_PI_Submissions.pdf	Cervical dystonia	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Jul 26, 2017	SR0512-000
Glatiramer acetate	Glatect	Glatiramer acetate	cdr_SE0510_Glatect.pdf SE0510_complete_Glatect-Jul-27-e.pdf SE0510_Glatect _PI_Submissions.pdf SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf	Relapsing Remitting Multiple Sclerosis (RRMS)	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 25, 2017	SE0510-000
Etanercept	Erelzi	Etanercept	cdr_SE0513_TBC.pdf SE0513_complete_Erelzi_Jul_28_17_e.pdf SE0513_Erelzi_SEB_Report.pdf SE0513_Erelzi_PI_Submissions.pdf	Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Feb 2, 2017	Jul 25, 2017	SE0513-000
Obeticholic Acid	Ocaliva	Obeticholic Acid	cdr_SR0509_TBC.pdf SR0509_complete_Ocaliva_Jul_27_17_e.pdf SR0509_Ocaliva_CL_Report_e.pdf SR0509_Ocaliva_PE_Report_e.pdf SR0509 Ocaliva_PI_Submissions.pdf	Primary Biliary Cholangitis	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2016	Jul 25, 2017	SR0509-000
Ninlaro for Multiple Myeloma –...	Ninlaro	Ixazomib	pcodr_provfund_ixazomib_ninlaro_mm.pdf pcodr_ixazomib_ninlaro_mm_fn_rec.pdf pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf pcodr_ixazomib_ninlaro_mm_fn_egr.pdf pcodr_ixazomib_ninlaro_mm_in_rec.pdf pcodr_ixazomib_ninlaro_mm_pagfdk.pdf pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf pcodr_ixazomib_ninlaro_mm_ptfdk.pdf pcodr_ixazomib_ninlaro_mm_clnfdk.pdf pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf pcodr_ixazomib_ninlaro_mm_coi_cln.pdf	Multiple Myeloma	Do not reimburse	Complete	Dec 16, 2016	Jun 29, 2017	PC0088-000
Daclizumab beta	Zinbryta	Daclizumab beta	cdr_SR0508_Zinbryta.pdf SR0508_compelte_Zinbryta_Jun-22-17_e.pdf SR0508_Zinbryta_CL_Report.pdf SR0508_Zinbryta_PE_Report.pdf SR0508_Zinbryta_PI_Submissions.pdf	Multiple Sclerosis, relapsing-remitting	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2016	Jun 20, 2017	SR0508-000
Gazyva for Follicular Lymphoma...	Gazyva	Obinutuzumab	pcodr_profund_obinutuzumab_gazyva_fl.pdf pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf media:document:b525feb5-dfab-4fab-9329-39565d03e75a media:document:e96c2560-fd09-4813-ac09-a3cef1e32514 pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf	Follicular Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 4, 2016	Jun 2, 2017	PC0091-000
Edoxaban	Lixiana VTE	Edoxaban	cdr_SR0499_Lixiana_VTE.pdf SR0499_complete_Lixiana_VTE_May_29_17_e.pdf SR0499_Lixiana_VTE_CL_Report.pdf SR0499_Lixiana_VTE_PE_Report.pdf	Venous thromboembolism, treatment and recurrence prevention.	Reimburse with clinical criteria and/or conditions	Complete	Sep 9, 2016	May 25, 2017	SR0499-000
emtricitabine/rilpivirine/ ten...	Odefsey	emtricitabine/rilpivirine/ tenofovir alafenamide	cdr_SR0507_TBC.pdf SR0507_complete_Odefsey- May-25-17_e.pdf SR0507_Odefsey_Combined_Report.pdf SR0507_Odefsey_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Nov 24, 2016	May 25, 2017	SR0507-000
Ivabradine	Lancora	Ivabradine	cdr_SR0506_Lancora.pdf SR0506_complete_Lancora-Jun15-17_e.pdf SR0506_ Lancora_CL_Report.pdf SR0506_ Lancora_PE_Report.pdf SR0506_Lancora_PI_Submissions.pdf	Heart failure, NYHA class II or III	Reimburse with clinical criteria and/or conditions	Complete	Nov 8, 2016	May 24, 2017	SR0506-000
Tagrisso for Non-Small Cell Lu...	Tagrisso	Osimertinib	pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 1, 2016	May 4, 2017	PC0076-000
Alecensaro for Non-Small Cell ...	Alecensaro	Alectinib	pcodr_provfund_alectinib_alecensaro_nsclc.pdf pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf	Non-Small Cell Lung Cancer	Do not reimburse	Complete	Oct 3, 2016	May 4, 2017	PC0092-000
Propiverine hydrochloride	Mictoryl	Propiverine hydrochloride	cdr_SR0504_Mictoryl.pdf SR0504_Mictoryl_CL Report.pdf SR0504_Mictoryl_PE_Report.pdf SR0504_Mictoryl_PI_Submissions.pdf SR0504_complete_Mictoryl_Apr-21-17-e.pdf	Overactive bladder (OAB)	Reimburse with clinical criteria and/or conditions	Complete	Oct 14, 2016	Apr 19, 2017	SR0504-000
Sarilumab	Kevzara	sarilumab	cdr_SR0503_TBC.pdf SR0503_Kevzara_CL_Report.pdf SR0503_Kevzara_PE_Report.pdf SR0503_Kevzara_PI_Submissions.pdf SR0503_complete_Kevzara-Apr-20-17.pdf	Arthritis, Rheumatoid	Reimburse with clinical criteria and/or conditions	Complete	Oct 12, 2016	Apr 18, 2017	SR0503-000
Mifepristone and misoprostol	Mifegymiso	Mifepristone and misoprostol	cdr_SR0502_Mifegymiso.pdf SR0502_complete_Mifegymiso-Apr-20-17-e.pdf SR0502_Mifegymiso_CL_Report.pdf SR0502_Mifegymiso_PE_Report.pdf	Medical termination of pregnancy (gestational age up to 49 days)	Reimburse	Complete	Oct 7, 2016	Apr 18, 2017	SR0502-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Health Technology Reassessment: An Overview of Canadian and International Processes		Mar 22, 2019			ES0334-000
Environmental Scan on Health Technology Reassessment Processes		Mar 22, 2019			ES0334-000
Reimbursement Status of Newer Drugs for the Treatment of Type 2 Diabetes		Feb 27, 2019	Environmental Scan	Completed	ES0337-000
Reimbursement of Newer Drugs for Type 2 Diabetes in Canada: An Environmental Scan		Feb 26, 2019	Environmental Scan	Completed	ES0337-000
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations		Jan 15, 2019	Optimal Use	Completed	OP0538-000 / CT0001
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma	media:document:d00ebe66-c3ca-4630-a5c9-9db0789e0f05 media:document:d878e503-9902-4b9a-b462-1c08b76ea345 media:document:db2f1690-ae45-427b-926d-e7e0b29a66b6	Jan 15, 2019	Optimal Use	Completed	OP0538-000 / CT0001
Detection and Diagnosis of Sepsis in Rural and Remote Areas: An Environmental Scan		Jan 9, 2019	Environmental Scan	Completed	ES0327-000
Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid Qualitative Review	Engaging with History Taking for Adverse Childhood Experiences in Care: A Rapid…	Nov 19, 2018	Rapid Review	Completed	RC1045-000
Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 26, 2018	Environmental Scan	Completed	ES0326-000
Recommendations Framework for Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 22, 2018			ES0326-000
Drugs for the Management of Rheumatoid Arthritis		Apr 25, 2018	Health Technology Assessment	Completed	HT0010-000
Use of Real-World Evidence in Single-Drug Assessments Environmental Scan		Apr 18, 2018	Environmental Scan	Completed	ES0323-000
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status		Mar 28, 2018	Environmental Scan	Completed	ES0325-000
Drugs for Type 2 Diabetes: Second-Line Therapy Review Update		Feb 7, 2018	Therapeutic Review	Completed	TR0012-000
New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report		May 23, 2017			TR0012-000
Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations		Dec 9, 2016	Environmental Scan	Completed	ES0293-000
Guidance Document for the Costing of Health Care Resources in the Canadian Setting: Second Edition		Mar 30, 2016			MH0002-CP0009
Drugs for Rare Diseases: Evolving Trends in Regulatory and Health Technology Assessment Perspectives	ES0300_Rare_Disease_Drugs_e.pdf	Feb 11, 2016			ES0300-000
Pruning Emtree: Does Focusing Embase Subject Headings Impact Search Strategy Precision and Sensitivity?	ATS0022_Pruning Emtree_Methods_Project_e.pdf	Apr 16, 2015
Drugs for Pulmonary Arterial Hypertension	TR0006-PAH-InBrief-e.pdf TR0006_PAH_Protocol_e.pdf TR0006_PAH_ScienceReport.pdf TR0006_PAH_Recs_Report.pdf	Mar 16, 2015			TR0006-000
Management of Relapsing-Remitting Multiple Sclerosis	TR0004_RRMS_PiB_e.pdf TR0004-000_RRMS_Protocol_e.pdf TR0004_RRMS_ScienceReport_e.pdf TR0004_RRMS_RecsReport_TR_e.pdf	Nov 29, 2012			TR0004-000
Second and Third-Line Therapy for Patients With Diabetes (Optimal Use Project)	OP0512_Diabetes_Update_PiB_e.pdf OP0512_Diabetes_RecsReport_2nd_3rd-line_e.pdf OP0512_DiabetesUpdate_Second-line_e.pdf OP0512_Diabetes Update_Third-line_e.pdf OP0512_DiabetesUpdate_Incretins-Insulin_e.pdf OU_DiabetesUpdate_Protocol_e.pdf	Dec 29, 2010			OP0512-000
Self-Monitoring of Blood Glucose	C1109_bgts_summary_report_e.pdf C1109-Project-in-Brief-final-e.pdf C1109-Gaps-and-KM-Report-final.pdf compus_BGTS_OT_Rec_e.pdf compus_Current_Practice_Report_Vol-3-Issue-5.pdf compus_CU_Report-BGTS.pdf BGTS_Consolidated_Economic_Report.pdf BGTS_SR_Report_of_Clinical_Outcomes.pdf BGTS_Summary_Protocol_FINAL.pdf	Nov 29, 2010
Portable Monitoring Devices for Diagnosis of Obstructive Sleep Apnea at Home: Review of Accuracy, Cost-Effectiveness, Guidelines, and Coverage in Canada	M0002_Executive Summary_e.pdf M0002_Portable_Monitoring_Devices_Obstructive_Sleep_Apnea_L3_e.pdf	Dec 9, 2009			M0002-000
Development and Testing of Search Filters to Identify Economic Evaluations in MEDLINE and EMBASE	H0490_Executive_Summary_e.pdf H0490_Search_Filters_for_Economic_Evaluations_mg_e.pdf	Oct 30, 2009

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Tocilizumab (Actemra) for the Treatment of Hospitalized Patients With COVID-19		Systematic Review — September 2023 Summary Report — September 2023	Sep 13, 2023	Health Technology Review	Systematic Review	Completed	RE0049-000
Nirmatrelvir-Ritonavir (Paxlovid) for the Treatment of COVID-19		Systematic Review, September 2023 Summary Report, September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0042-000
Remdesivir (Veklury) for the Treatment of COVID-19 in the Outpatient Setting		Systematic Review — September 2023 Summary Report — September 2023	Sep 12, 2023	Health Technology Review	Health Technology Assessment	Completed	HT0041-000
abiraterone acetate and prednisolone		Recommendation and Reasons Stakeholder Input Stakeholder Feedback on Draft Recommendation Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report	Sep 11, 2023	Reimbursement Review		Complete	PX0291-000 - PC0291-000
dapagliflozin		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	SX0749-000 - SR0749-000
abiraterone, prednisone, docetaxel		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Sep 8, 2023	Reimbursement Review		Complete	PX0298-000 - PC0298-000
Timing of Ventilator Circuit Tubing Replacement		Timing of Ventilator Circuit Tubing Replacement	Sep 8, 2023	Health Technology Review	Rapid Review	Completed	RC1498-000
Telephone Triage Services	Telephone triage programs provide timely access to trained health care professionals who can assess a patient’s symptoms over the phone and provide self-care advice or referral to an appropriate level of care.	canadian_telephone_triage_programs_infographic.pdf Telephone Triage Services	Sep 7, 2023	Health Technology Review	Environmental Scan	Completed	ES0378-000
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)		Implementation Advice	Aug 30, 2023	Health Technology Review	Technology Review	Completed	HC0060-000
vericiguat		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 30, 2023	Reimbursement Review		Complete	SR0758-000
atogepant		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Aug 30, 2023	Reimbursement Review		Complete	SR0724-000
upadacitinib		Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 28, 2023	Reimbursement Review		Complete	SR0759-000
Issues in Pediatric Health Care	Shortage events, the phenomena when demand exceeds supply, can affect both medical care and medical devices. The COVID-19 pandemic caused a global shortage event, the consequences of which are still being experienced beyond the peak of the pandemic (e.g., the lack of pediatric pain medication available in fall 2022).	Issues in Pediatric Health Care	Aug 25, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0116-000
Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation		Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation	Aug 22, 2023	Health Technology Review	Rapid Review	Completed	RC1500-000
Artificial Intelligence in Prehospital Emergency Health Care	Health care systems in Canada, including prehospital emergency health care services, are facing staffing shortages and increased patient volumes, and are looking for creative solutions to ensure the provision of high-quality care.	Artificial Intelligence in Prehospital Emergency Health Care	Aug 18, 2023	Horizon Scan	Health Technology Update	Completed	EN0052-000
Utilization of Opioid Agonist Therapies in Canada		Utilization of Opioid Agonist Therapies in Canada	Aug 15, 2023	Health Technology Review	Technology Review	Completed	HC0064-000
cariprazine		Memorandum report to CADTH Response to the Procedural Review Panel’s Memorandum Report on the Procedural R…Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Aug 10, 2023	Reimbursement Review		Complete	SR0708-000
Non-Small Cell Lung Cancer without actionable oncogenic alterations		Final Report	Aug 10, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0029-000
Lipid Panel Screening for Adults Living With Chronic Conditions		Lipid Panel Screening for Adults Living With Chronic Conditions	Aug 10, 2023	Health Technology Review	Rapid Review	Completed	RC1497-000
Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Outcomes in Infants		Cost-Effectiveness of an RSVpreF Vaccine for Prevention of Respiratory Syncytia…	Aug 8, 2023	Health Technology Review	Technology Review	Complete	HE0044-000
Somatropin for Turner Syndrome		Somatropin for Turner Syndrome	Aug 4, 2023	Health Technology Review	Rapid Review	Completed	RC1493-000
Somatropin for Growth Hormone Deficiency		Somatropin for Growth Hormone Deficiency	Aug 4, 2023	Health Technology Review	Rapid Review	Completed	RC1492-000
At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders		At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders	Aug 4, 2023	Health Technology Review	Rapid Review	Completed	RC1495-000
ciltacabtagene autoleucel		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Aug 2, 2023	Reimbursement Review		Complete	PG0302-000
palovarotene		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Aug 1, 2023	Reimbursement Review		Complete	SR0761-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81